Completed PHASE2 INTERVENTIONAL 1-arm NCT00818181

Open Label Safety Study of a Birch Pollen Allergen Extract

A Multicentre Open Label Safety Study of a Sublingual Specific Immunotherapy With a Solution of Birch Pollen Allergen Extract in Patients With Clinically Relevant Birch Pollen Allergy

Sponsor: Allergopharma GmbH & Co. KG

Conditions Rhinoconjunctivitis

Interventions Biological: AL0206st

Updated 5 times since 2017 Last updated: Mar 8, 2013 Started: Jun 30, 2008 Primary completion: Feb 28, 2009 Completion: Aug 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Rhinoconjunctivitis and is currently completed. Allergopharma GmbH & Co. KG leads this study, which shows 5 recorded versions since 2008 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Jun 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Allergopharma GmbH & Co. KG

Data source: Allergopharma GmbH & Co. KG

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Cologne, Germany